Corrected: RxSight says Q2 results hit by more widespread competitive trialing

RxSight

06/07/2026 21:35

Corrects throughout to report total revenue figures, instead of sales figures that the company includes as one part of total revenue; the story was previously corrected to remove an extraneous word in the headline

Overview
US ophthalmic device maker expects preliminary Q2 total revenue of $32 mln to $34 mln
Company faced commercial headwinds in Q2, including more widespread competitive trialing
Company raises 2026 gross margin outlook

Outlook
RxSight expects 2026 total revenue of $140 mln to $160 mln 
Company raises 2026 gross margin outlook to 73%-75% from 70%-72%
RxSight still expects 2026 operating costs at high-end of $150 mln-$160 mln range

Result Drivers
COMPETITIVE PRESSURE - Co said more widespread competitive trialing created commercial headwinds in Q2
LAL SALES - Sales included 24,917 Light Adjustable Lens units and 11 Light Delivery Devices
TOTAL REVENUE - Q2 revenue includes sales of about $27 million, and $5-$7 mln from Alcon strategic collaboration

Company press release: ID:nGNX6ZPtfG

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Prelim Total Revenue
 
$32-$34 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Rxsight Inc is $9.00, about 60.4% above its July 2 closing price of $5.61

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)